Argent BioPharma Ltd (RGT)

Sydney
Currency in AUD
0.150
+0.035(+30.43%)
Closed·
RGT Scorecard
Full Analysis
Operates with a significant debt burden
RGT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1200.150
52 wk Range
0.1100.570
Key Statistics
Edit
Bid/Ask
0.12 / 0.15
Prev. Close
0.115
Open
0.12
Day's Range
0.12-0.15
52 wk Range
0.11-0.57
Volume
30.46K
Average Volume (3m)
36.95K
1-Year Change
-67.9%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RGT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
May have trouble making interest payments on debt
No news in this category
Looks like there are no results in this news category

Argent BioPharma Company Profile

Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment. The company has collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Compare RGT to Peers and Sector

Metrics to compare
RGT
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.9x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
−0.6x1.6x2.6x
Price / LTM Sales
23.0x8.3x2.9x
Upside (Analyst Target)
-253.0%53.4%
Fair Value Upside
Unlock13.1%10.2%Unlock

Earnings

Latest Release
Feb 28, 2025
EPS / Forecast
-0.24 / --
Revenue / Forecast
4.28K / --
EPS Revisions
Last 90 days

FAQ

What Is the Argent BioPharma (RGT) Stock Price Today?

The Argent BioPharma stock price today is 0.15

What Stock Exchange Does Argent BioPharma Trade On?

Argent BioPharma is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Argent BioPharma?

The stock symbol for Argent BioPharma is "RGT."

What Is the Argent BioPharma Market Cap?

As of today, Argent BioPharma market cap is 8.89M.

What Is Argent BioPharma's Earnings Per Share (TTM)?

The Argent BioPharma EPS (TTM) is -0.45.

When Is the Next Argent BioPharma Earnings Date?

Argent BioPharma will release its next earnings report on 27 May 2025.

From a Technical Analysis Perspective, Is RGT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.